Monitor for any future conversion of this passive 13G filing to a 13D (activist) filing, which would signal a change in intent. The stake is at the 9.99% cap, limiting further accumulation without exceeding the beneficial ownership limitation.
XLO drugs
XLO drug pipeline →Price Chart
How similar events traded
Executive Summary
Coastlands Capital LP filed an amended Schedule 13G disclosing a 9.99% passive beneficial ownership stake in Xilio Therapeutics, holding 731,573 shares (including pre-funded warrant shares) as of September 30, 2026. The amendment reflects a reverse stock split and recent transactions, with the stake remaining at the 9.99% beneficial ownership limitation cap.
Key Financial Metrics
Key Facts
- Coastlands Capital LP and related entities hold 731,573 shares of Xilio common stock, representing 9.99% beneficial ownership.
- The stake includes shares issuable upon exercise of pre-funded warrants, subject to a 9.99% beneficial ownership limitation.
- The filing is an amendment to reflect a reverse stock split and transactions in common stock.
- The stake is passive, with no intent to change or influence control of the issuer.
- The filing date is November 13, 2026, with ownership as of September 30, 2026.
Financial Impact
9.99% beneficial ownership stake, valued at approximately $6.0M based on $60M market cap.
Risk Factors
- The filing does not disclose the exact number of shares held outright versus those issuable upon warrant exercise, creating some ambiguity about actual economic exposure.
- A passive filing at the 9.99% cap may precede a shift to active engagement if the investor's thesis changes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001104659-26-127419 |
| Document: 0001104659-26-127419-index.html | 0001104659-26-127419 |
| Document: 0001104659-26-127419.txt | 0001104659-26-127419 |
Track record
16 reports on XLO
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +19.92% at T+60 after the May 12, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $7.70 Now $7.70 −0.00% settles Nov 24
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Viewing Entry $7.96 Now $7.70 −3.27% settles Nov 23
- Nov 12, 20264d ago SC 13G Neutral 4/10 Entry $8.24 Now $7.70 −6.55% settles Nov 19
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $8.53 Now $7.70 −9.73% settles Nov 17
- Oct 26, 202621d ago Press Release Neutral 4/10 Entry $7.31 to $8.03 Now $7.70 +5.34% ▲ +9.85% +11.11% vs SPY
- Aug 12, 202613w ago 8-K Bullish 7/10 No price data
- Aug 12, 202613w ago Press Release Bullish 7/10 Entry $9.05 to $9.41 Now $7.70 −14.92% ▲ +3.98% +4.42% vs SPY
- Jun 1, 202624w ago EFFECT Bearish 5/10 Entry $8.25 to $7.70 Now $7.70 +6.67% ▲ +6.67% +3.92% vs SPY
- May 27, 202624w ago S-3/A Neutral 4/10 Entry $8.52 to $8.15 Now $7.70 −9.62% ▼ −4.40% −4.35% vs SPY
- May 12, 202626w ago 8-K Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers